119 related articles for article (PubMed ID: 27443893)
1. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer.
Nosaka K; Shibata K; Utsumi F; Yoshida K; Niimi K; Sekiya R; Suzuki S; Kajiyama H; Kikkawa F
Tumori; 2016 Dec; 102(6):600-605. PubMed ID: 27443893
[TBL] [Abstract][Full Text] [Related]
2. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
5. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
[TBL] [Abstract][Full Text] [Related]
6. Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients: a phase 2 trial.
Mitsuhashi A; Uno T; Usui H; Nishikimi K; Yamamoto N; Watanabe M; Tate S; Hirashiki K; Kato K; Yamazawa K; Shozu M
Int J Gynecol Cancer; 2013 Oct; 23(8):1453-8. PubMed ID: 23266648
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of survivals and toxicities between young and elderly patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy.
Wang W; Liu X; Meng Q; Zhang F; Hu K
Taiwan J Obstet Gynecol; 2019 May; 58(3):364-369. PubMed ID: 31122526
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
12. Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer.
Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Obstet Gynaecol Res; 2015 Oct; 41(10):1638-43. PubMed ID: 26177790
[TBL] [Abstract][Full Text] [Related]
13. Impact of chemotherapy cycles on oncological outcomes in elders with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Tangkananan A; Thongkhao P; Janmunee N; Hanprasertpong J
J Med Imaging Radiat Oncol; 2022 Oct; 66(7):1014-1021. PubMed ID: 35695633
[TBL] [Abstract][Full Text] [Related]
14. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy or radiotherapy alone for locally advanced cervical cancer in elderly women.
Park JH; Kim YS; Ahn SD; Choi EK; Shin SS; Kim YT; Kim YM; Kim JH; Yi SY; Nam JH
Tumori; 2010; 96(6):959-65. PubMed ID: 21388059
[TBL] [Abstract][Full Text] [Related]
16. Triple-modality treatment in patients with advanced stage tonsil cancer.
Roden DF; Schreiber D; Givi B
Cancer; 2017 Sep; 123(17):3269-3276. PubMed ID: 28440876
[TBL] [Abstract][Full Text] [Related]
17. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.
Song S; Song C; Kim HJ; Wu HG; Kim JH; Park NH; Song YS; Kim JW; Kang SB; Ha SW
Gynecol Oncol; 2012 Jan; 124(1):63-7. PubMed ID: 22004904
[TBL] [Abstract][Full Text] [Related]
18. Postoperative concurrent chemoradiotherapy for the high-risk uterine cervical cancer.
Takeshita S; Kita T; Motoike Y; Umezawa K; Sugisaki S; Matsumoto S; Matsumoto Y; Ryo E; Ayabe T
J Obstet Gynaecol Res; 2010 Oct; 36(5):1009-14. PubMed ID: 20722988
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
Nam H; Park W; Huh SJ; Bae DS; Kim BG; Lee JH; Lee JW; Lim DH; Han Y; Park HC; Ahn YC
Gynecol Oncol; 2007 Nov; 107(2):320-5. PubMed ID: 17675222
[TBL] [Abstract][Full Text] [Related]
20. Postoperative concurrent daily low-dose cisplatin-based chemoradiation improves the prognosis of patients with pathologic T2b or N1 cervical cancer.
Mitsuhashi A; Uno T; Usui H; Tate S; Hirashiki K; Kato K; Kiyohara H; Kato S; Ito H; Shozu M
Anticancer Res; 2010 Jun; 30(6):2341-6. PubMed ID: 20651390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
